V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016547 | 160020529 | 1.82 | 44.3 | Adjuvant (A) | 2020-07-14 | 2020-07-21 | Bevacizumab 15mg/kg | 02 | N | LIPOSOMAL DOXORUBICIN | 100387025 |
| 160016640 | 160020530 | 1.64 | 12.1 | null | 2019-11-14 | 2021-03-24 | STS Rhabdomyosarcoma RMS 2005 IVA | null | null | STS RHABDO RMS 2005 VIN CYCLO | 100225927 |
| 160016710 | 160020531 | 1.86 | 51.4 | Curative (C) | 2016-11-25 | 2017-02-19 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | N | IFOSFAMIDE | 100954690 |
| 160016749 | 160020532 | 0 | 89.8 | Curative (C) | 2020-02-03 | 2020-03-20 | Ifosfamide | N | N | DOXORUBICIN + IFOSFAMIDE | 100080250 |
| 160016779 | 160020533 | 1.75 | 9.6 | Palliative (P) | 2022-01-31 | 2022-04-04 | Etoposide oral | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 100909788 |
| 160016868 | 160020534 | 1.66 | 93.7 | null | 2021-02-26 | 2021-03-05 | NB HRNBL-1 BUMEL MAT | 02 | null | TRIAL | 101197738 |
| 160016975 | 160020537 | 1.97 | 111.05 | Curative (C) | 2021-02-21 | 2021-02-23 | ICON8B TRIAL | 02 | N | GEMCITABINE | 100761456 |
| 160016993 | 160020538 | 1.8 | 11.2 | null | 2021-05-11 | 2021-06-02 | Gemcitabine day 1&8 | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 100212183 |
| 160017140 | 160020539 | 1.56 | 59.6 | Palliative (P) | 2021-11-22 | 2021-12-28 | STS Rhabdo RMS 2005 2nd Topo Carbo | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100022048 |
| 160017159 | 160020540 | 1.68 | 18 | 02 | 2021-09-03 | 2021-09-24 | Doxorubicin + Ifosfamide | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 101794810 |
| 160017164 | 160020541 | 0 | null | null | 2020-03-02 | 2020-12-11 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | CARBOPLATIN + DOCETAXEL | 100139910 |
| 160017216 | 160020542 | 1.6 | 68 | Neo-adjuvant (N) | 2020-02-23 | 2020-03-05 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101196585 |
| 160017419 | 160020543 | null | 14.8 | Curative (C) | 2016-04-10 | 2016-10-29 | null | 02 | N | TRIAL | 100343892 |
| 160002009 | 160020544 | 1.7 | 60.3 | Curative (C) | 2017-09-22 | 2020-09-12 | NB BEACON Temozolomide Topotecan | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100169851 |
| 160005199 | 160020545 | 1.67 | 92.5 | Neo-adjuvant (N) | 2019-11-12 | 2019-12-11 | STS Rhabdo RMS 2005 Vin Cyclo | N | N | DOXORUBICIN + IFOSFAMIDE | 100797738 |
| 160010801 | 160020546 | 1.45 | 63.9 | null | 2017-09-30 | 2017-12-17 | EW EuroEwing 2012 Arm B VDC | 02 | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 100508709 |
| 160016734 | 160020547 | 1.81 | 55.1 | 03 | 2019-06-30 | 2019-08-28 | CEDIRANIB | 02 | N | NB HRNBL-1 ISOTRETINOIN | 100068510 |
| 160015343 | 160020561 | 1.74 | 61.2 | Palliative (P) | 2022-04-23 | 2022-05-01 | Doxorubicin 75mg/m2 | N | N | NIVOLUMAB | 100568238 |
| 160015535 | 160020562 | 1.75 | 132.7 | Palliative (P) | 2020-06-16 | 2020-07-01 | DOXORUBICIN | 02 | N | DOXORUBICIN | 101424685 |
| 160015679 | 160020563 | 1.5 | 116.1 | Palliative (P) | 2021-09-13 | 2021-09-16 | NIVOLUMAB | 02 | N | NIVOLUMAB | 100494943 |
| 160015969 | 160020564 | 1.7 | 68 | null | 2018-12-20 | 2019-01-25 | Trabectedin | 02 | null | TRABECTEDIN | 101127652 |
| 160016215 | 160020565 | 1.73 | 74.5 | null | 2018-09-26 | 2018-10-12 | Bevacizumab | null | null | DOXORUBICIN + OLARATUMAB | 101711099 |
| 160016304 | 160020566 | 1.63 | 77 | Palliative (P) | 2019-12-08 | 2020-01-02 | Carboplatin AUC 2 - 5 | 02 | Y | CARBOPLATIN | 100017071 |
| 160016323 | 160020567 | 1.77 | 75 | Neo-adjuvant (N) | 2021-11-03 | 2022-04-03 | Bevacizumab 15mg/kg | 02 | N | CISPLATIN + PEMETREXED | 101402071 |
| 160016440 | 160020568 | 1.72 | 67.8 | Neo-adjuvant (N) | 2020-01-01 | 2020-01-08 | CARBOPLATIN | 02 | N | CARBOPLATIN | 100907107 |
| 160016447 | 160020569 | 1.67 | 51.6 | Palliative (P) | 2021-02-12 | 2021-06-18 | Doxorubicin + Olaratumab | 02 | N | DOXORUBICIN + OLARATUMAB | 101003237 |
| 160016547 | 160020571 | 1.53 | 0 | Palliative (P) | 2020-07-07 | 2020-08-21 | Bevacizumab | 02 | N | PACLITAXEL | 100387025 |
| 160016640 | 160020572 | 1.51 | 64.8 | Palliative (P) | 2021-01-07 | 2021-07-05 | PACLITAXEL | 02 | N | PACLITAXEL | 100225927 |
| 160016710 | 160020573 | 1.76 | 85 | Neo-adjuvant (N) | 2017-03-05 | 2017-03-19 | Liposomal Doxorubicin 40mg/m2 | 02 | N | LIPOSOMAL DOXORUBICIN | 100954690 |
| 160016749 | 160020574 | 1.81 | 88.2 | Adjuvant (A) | 2020-04-05 | 2020-04-19 | Bevacizumab 7.5mg/kg | 02 | N | CARBOPLATIN + PACLITAXEL | 100080250 |
| 160016779 | 160020575 | 1.44 | 78.1 | Palliative (P) | 2022-02-23 | 2022-04-19 | Bevacizumab 7.5mg/kg | 02 | N | CARBOPLATIN + GEMCITABINE | 100909788 |
| 160016868 | 160020576 | 0 | 82.3 | Palliative (P) | 2021-04-08 | 2021-04-08 | EW EuroEwing 2012 Arm A VAI | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 101197738 |
| 160017159 | 160020580 | 1.65 | 15.8 | null | 2021-10-11 | 2021-10-17 | Trial Unspecified | 02 | null | CISPLATIN + GEMCITABINE | 101794810 |
| 160017164 | 160020581 | 1.54 | 14.8 | Palliative (P) | 2020-07-13 | 2020-12-14 | Ifosfamide PVI 1g/m2 14day | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100139910 |
| 160017216 | 160020582 | 1.6 | 12.9 | Palliative (P) | 2020-04-20 | 2020-04-30 | PEMBROLIZUMAB | 02 | N | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 101196585 |
| 160017419 | 160020583 | 1.64 | 73.35 | Palliative (P) | 2016-05-08 | 2016-11-24 | Doxorubicin + Ifosfamide | 02 | Y | NB HRNBL-1 COJEC IND COURSE C | 100343892 |
| 160002009 | 160020584 | 1.66 | 70.6 | Neo-adjuvant (N) | 2019-12-03 | 2020-08-12 | Ribociclib | 02 | N | CYCLOPHOSPHAMIDE + VINCRISTINE | 100169851 |
| 160005199 | 160020585 | 1.83 | 55.65 | null | 2020-01-03 | 2020-01-03 | LIPOSOMAL DAUNORUBICIN | 02 | null | PEMBROLIZUMAB | 100797738 |
| 160010801 | 160020586 | 0 | 15.1 | Curative (C) | 2018-03-21 | 2018-04-11 | null | 02 | N | CYCLOPHOSPHAMIDE | 100508709 |
| 160016734 | 160020587 | null | 121.4 | null | 2021-02-10 | 2021-02-20 | Doxorubicin + Ifosfamide | N | N | IPILIMUMAB + NIVOLUMAB | 100068510 |
| 160015535 | 160020596 | null | null | null | 2020-05-13 | 2020-06-03 | null | 02 | null | CARBOPLATIN + PEMETREXED | 101424685 |
| 160016215 | 160020598 | 1.79 | 83.1 | null | 2018-09-14 | 2018-09-19 | Doxorubicin 75mg/m2 | N | null | DOXORUBICIN | 101711099 |
| 160016323 | 160020599 | 1.88 | 79.4 | null | null | 2022-05-24 | Carboplatin AUC 2 - 5 | 02 | null | CARBOPLATIN | 101402071 |
| 160016447 | 160020600 | 1.51 | 92.2 | Neo-adjuvant (N) | 2021-05-09 | 2021-07-18 | Bevacizumab 7.5mg/kg | 02 | N | CARBOPLATIN | 101003237 |
| 160016547 | 160020602 | 1.74 | 62 | Palliative (P) | 2020-07-14 | 2020-09-14 | DOCETAXEL + GEMCITABINE | 02 | N | DOCETAXEL + GEMCITABINE | 100387025 |
| 160016749 | 160020603 | 1.69 | 74 | Adjuvant (A) | 2020-04-18 | 2020-05-18 | Bevacizumab 7.5mg/kg | 02 | N | CARBOPLATIN + PACLITAXEL | 100080250 |
| 160016868 | 160020605 | 1.76 | 95 | null | 2021-06-16 | 2021-06-17 | Bevacizumab | 02 | null | CARBOPLATIN + GEMCITABINE | 101197738 |
| 160016993 | 160020608 | null | 104 | Curative (C) | 2021-08-03 | 2021-08-06 | STS Rhabdomyosarcoma RMS 2005 IVA | 01 | N | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100212183 |
| 160017216 | 160020609 | 1.65 | 9.9 | null | 2020-05-01 | 2020-06-24 | ARIEL 4 Trial | N | null | DOXORUBICIN + IFOSFAMIDE | 101196585 |
| 160002009 | 160020610 | 1.82 | 45.9 | 03 | 2019-11-07 | 2020-09-08 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | NIRAPARIB | 100169851 |